Walgreens Boots Alliance dividend reset, shares face cautious analyst tone

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-29, 11:20.

Walgreens Boots Alliance, Inc. (US9314271019) earlier this year cut its quarterly dividend by 48 percent to 0.25 dollars per share, a marked shift in capital allocation as the company pursues a multi-year turnaround on the Nasdaq, as detailed in its January 2024 investor update. Walgreens Boots Alliance Q1 2024 IR release on dividend reduction

Dividend cut frames the turnaround

The board of Walgreens Boots Alliance, Inc. announced in January 2024 that it would reduce the quarterly dividend from 0.48 dollars to 0.25 dollars per share starting with the fiscal first quarter, aiming to free up roughly 800 million dollars annually for debt reduction and growth investments. Wall Street Journal coverage of Walgreens dividend policy shift

In the accompanying earnings release for fiscal Q1 2024, the pharmacy group reported adjusted earnings per share of 0.66 dollars, down from 1.16 dollars a year earlier, with management citing ongoing margin pressure in the US Retail Pharmacy segment and losses in the VillageMD primary-care unit as key drivers of the earnings decline. Fiscal Q1 2024 Walgreens Boots Alliance earnings release

Analyst stance stays cautious

Several major research houses have reacted cautiously to Walgreens Boots Alliance, Inc. since the dividend decision and subsequent results, with JPMorgan maintaining a Neutral stance and price target of 23 dollars, and Morgan Stanley rating the stock Equal-Weight, citing execution risks in healthcare services and the need for clearer profitability trends. MarketScreener consensus overview for Walgreens Boots Alliance

Consensus data collated in late June 2026 show around 17 analysts covering Walgreens Boots Alliance, Inc., with roughly three Buy ratings, nine Holds and five Sells, and an average 12-month price target near 23 dollars, implying limited expected upside from the recent trading range just under 20 dollars on the Nasdaq. Finanzen.net analyst summaries for Walgreens Boots Alliance

What Walgreens Boots Alliance sells

Walgreens Boots Alliance, Inc. generates most of its revenue from its US Retail Pharmacy business, which runs around 8,000 Walgreens drugstores offering prescription medications, over-the-counter drugs and front-of-store merchandise such as health, beauty and personal care goods. Walgreens Boots Alliance 2023 annual report business description

Where Walgreens Boots Alliance stock trades today

Walgreens Boots Alliance, Inc. stock most recently traded around 19.50 dollars on the Nasdaq, with prices in late June 2026 reflecting the impact of the dividend cut and cautious earnings guidance as of 2026-06-29, 11:15.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.